MCID: IMP006
MIFTS: 43

Impulse Control Disorder

Categories: Mental diseases

Aliases & Classifications for Impulse Control Disorder

MalaCards integrated aliases for Impulse Control Disorder:

Name: Impulse Control Disorder 12 15
Disruptive, Impulse Control, and Conduct Disorders 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10937
ICD10 33 F63.9
ICD9CM 35 312.30
MeSH 44 D007174
NCIt 50 C34723
UMLS 73 C0021122

Summaries for Impulse Control Disorder

Disease Ontology : 12 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others.

MalaCards based summary : Impulse Control Disorder, also known as disruptive, impulse control, and conduct disorders, is related to trichotillomania and pathological gambling. An important gene associated with Impulse Control Disorder is ANKK1 (Ankyrin Repeat And Kinase Domain Containing 1), and among its related pathways/superpathways are Dopamine-DARPP32 Feedback onto cAMP Pathway and Circadian rythm related genes. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity –... more...

Related Diseases for Impulse Control Disorder

Diseases related to Impulse Control Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 32.0 CLNK DLGAP3 SLITRK1
2 pathological gambling 30.8 DRD2 DRD3 DRD4
3 alexithymia 29.9 ANKK1 DRD2
4 gilles de la tourette syndrome 29.3 DRD2 DRD4 SLITRK1
5 parkinson disease, late-onset 28.3 DRD2 DRD3 DRD4
6 disease of mental health 28.0 DRD2 DRD3 DRD4 GRN
7 obsessive-compulsive disorder 27.6 DLGAP3 DRD2 DRD3 DRD4 SLITRK1
8 kleptomania 11.3
9 pyromania 11.1
10 intermittent explosive disorder 10.9
11 kluver-bucy syndrome 10.9
12 follicular mucinosis 10.3 DLGAP3 SLITRK1
13 stereotypic movement disorder 10.3 CLNK SLITRK1
14 taqi polymorphism 10.3 ANKK1 DRD2
15 antisocial personality disorder 10.2 ANKK1 DRD2
16 oppositional defiant disorder 10.1 DRD2 DRD4
17 supranuclear palsy, progressive, 1 10.0 DRD2 GRN
18 restless legs syndrome 10.0
19 conduct disorder 10.0 DRD2 DRD4
20 heroin dependence 10.0 ANKK1 DRD2 DRD4
21 depression 9.9
22 tic disorder 9.9 DRD2 DRD4 SLITRK1
23 polysubstance abuse 9.7 DRD2 DRD3
24 tardive dyskinesia 9.7 DRD2 DRD3
25 perry syndrome 9.7
26 dystonia 3, torsion, x-linked 9.7
27 alacrima, achalasia, and mental retardation syndrome 9.7
28 bipolar disorder 9.7
29 burns 9.7
30 withdrawal disorder 9.7
31 basal ganglia calcification 9.7
32 stuttering 9.7
33 social phobia 9.7
34 premature ejaculation 9.7
35 bipolar i disorder 9.7
36 epilepsy 9.7
37 dermatitis 9.7
38 dystonia 9.7
39 rem sleep behavior disorder 9.7
40 fibromyalgia 9.7
41 teratoma 9.6 CGA GRN
42 opiate dependence 9.6 DRD2 DRD3
43 cocaine dependence 9.5 DRD2 DRD3
44 drug dependence 9.4 ANKK1 DRD2 DRD3
45 delusional disorder 9.3 DRD2 DRD3 DRD4
46 early-onset schizophrenia 9.3 DRD2 DRD3 DRD4
47 migraine without aura 9.3 DRD2 DRD3 DRD4
48 personality disorder 9.3 DRD2 DRD3 DRD4
49 substance abuse 9.3 DRD2 DRD3 DRD4
50 substance dependence 9.3 DRD2 DRD3 DRD4

Comorbidity relations with Impulse Control Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Impulse Control Disorder:



Diseases related to Impulse Control Disorder

Symptoms & Phenotypes for Impulse Control Disorder

GenomeRNAi Phenotypes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.6 DRD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 DRD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.6 DRD3 DRD4 CLNK
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.6 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.6 CLNK
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.6 DRD3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.6 DRD3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.6 DRD3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.6 DRD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.6 CLNK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.6 DRD3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.6 DRD3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.6 CLNK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.6 DRD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.6 DRD3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.6 CLNK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 DRD3

MGI Mouse Phenotypes related to Impulse Control Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.17 CGA DLGAP3 DRD2 DRD3 DRD4 GRN

Drugs & Therapeutics for Impulse Control Disorder

Drugs for Impulse Control Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Nicotine Approved Phase 4,Phase 2 54-11-5 942 89594
4
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
6
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
7
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
8
Carbidopa Approved Phase 4 28860-95-9 34359 38101
9
Levodopa Approved Phase 4,Phase 3 59-92-7 6047
10
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
13
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
14
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
15
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
16
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
17
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
18
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
19
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
20 Central Nervous System Stimulants Phase 4,Phase 2
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Dopamine Uptake Inhibitors Phase 4,Phase 2,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
25 Autonomic Agents Phase 4,Phase 3,Phase 2
26 Cholinergic Agents Phase 4,Phase 2
27 Nicotinic Agonists Phase 4,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anticonvulsants Phase 4,Phase 2
30 Anti-Obesity Agents Phase 4,Phase 2
31 Neuroprotective Agents Phase 4,Phase 2
32 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Dopamine agonists Phase 4,Phase 3,Phase 2,Not Applicable
34 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
38 Antidepressive Agents Phase 4,Phase 2,Not Applicable
39 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
40 Serotonin Agents Phase 4,Phase 3,Phase 2
41 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
42 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
43 Cholinergic Antagonists Phase 4
44 Muscarinic Antagonists Phase 4
45 Parasympatholytics Phase 4
46 Monoamine Oxidase Inhibitors Phase 4
47 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
48 Antiemetics Phase 4,Phase 3,Phase 2
49 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
4 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
6 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
7 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
8 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
9 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
10 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4 pramipexole
11 Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression Completed NCT01078298 Phase 4 varenicline;placebo
12 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
13 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
14 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
15 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
16 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
17 A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients Completed NCT01631825 Phase 3 SPM 962
18 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
19 Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Completed NCT02242487 Phase 3 CVT-301
20 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
21 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
22 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
23 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
24 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
25 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Not yet recruiting NCT03146130 Phase 3
26 Dronabinol in Trichotillomania Not yet recruiting NCT03530800 Phase 2, Phase 3 Dronabinol;Placebo
27 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
28 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
29 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
30 Double-Blind Naltrexone in Compulsive Sexual Behavior Completed NCT00467558 Phase 2 Naltrexone;Sugar pill
31 Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET Completed NCT02039024 Phase 2 18F- DTBZ
32 N-Acetyl Cysteine in Pathologic Skin Picking Completed NCT01063348 Phase 2 N-Acetyl Cysteine;Placebo
33 Inositol in Trichotillomania Completed NCT01875445 Phase 2 Inositol;Placebo
34 A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome Completed NCT01562743 Phase 2 SPM 962
35 The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Completed NCT00464737 Phase 2 Rotigotine;Rotigotine
36 Memantine in the Treatment of Kleptomania Completed NCT00880685 Phase 2 Memantine
37 Double-Blind Naltrexone in Kleptomania Completed NCT00332579 Phase 2 Naltrexone;Placebo
38 A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED Completed NCT00127400 Phase 2
39 A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder Completed NCT00078754 Phase 2 Fluoxetine;Divalproex;Placebo
40 Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder Completed NCT02055638 Phase 1, Phase 2 SRX246;Placebo
41 Psychotherapy for Intermittent Explosive Disorder Completed NCT00667212 Phase 2
42 Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
43 D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
44 Trichotillomania: Group Cognitive-Behavioral Therapy Completed NCT01968343 Phase 2
45 Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
46 Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania Completed NCT01654523 Phase 2
47 Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Completed NCT01215357 Phase 2 Ecopipam
48 Stepped Care in the Treatment of Trichotillomania Completed NCT01118637 Phase 2
49 Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
50 N-Acetylcysteine for Pediatric Trichotillomania Completed NCT00993265 Phase 2 N-Acetylcysteine;Placebo

Search NIH Clinical Center for Impulse Control Disorder

Cochrane evidence based reviews: disruptive, impulse control, and conduct disorders

Genetic Tests for Impulse Control Disorder

Anatomical Context for Impulse Control Disorder

MalaCards organs/tissues related to Impulse Control Disorder:

41
Testes, Brain, Skin, Pituitary, Subthalamic Nucleus, Prefrontal Cortex, Cortex

Publications for Impulse Control Disorder

Articles related to Impulse Control Disorder:

(show top 50) (show all 86)
# Title Authors Year
1
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. ( 29198499 )
2018
2
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. ( 29753604 )
2018
3
Compulsive Sexual Behavior as an Impulse Control Disorder: Awaiting Field Studies Data. ( 29572770 )
2018
4
Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. ( 29066517 )
2017
5
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. ( 28346715 )
2017
6
Impulse control disorder and response-inhibition alterations in Parkinson's disease. A rare case of totally absent functionality of the medial-prefrontal cortex and review of literature. ( 29034115 )
2017
7
A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease. ( 28288482 )
2017
8
ISMP Adverse Drug Reactions: Pregabalin-Induced Stuttering Nitroglycerine-Induced Bradycardia Progressing to Asystole Minocycline-Induced DRESS Leading to Liver Transplantation and Type 1 Diabetes Increased Risk of Vertebral Fractures in Women Receiving Thiazide or Loop Diuretics Gambling Disorder and Impulse Control Disorder with Aripiprazole. ( 28515502 )
2017
9
Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. ( 28767029 )
2017
10
Depression, Impulse Control Disorder, and Life Style According to Smartphone Addiction. ( 29295357 )
2017
11
Electro-acupuncture treatment for internet addiction: Evidence of normalization of impulse control disorder in adolescents. ( 28861803 )
2017
12
Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism. ( 27997702 )
2017
13
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. ( 27930495 )
2017
14
Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report. ( 29213446 )
2016
15
Tattooing as a Symptom of Impulse Control Disorder in a Parkinsonian Patient With Pramipexole. ( 27749676 )
2016
16
18F-FDG -PET Correlates of Impulse Control Disorder In A Diabetic Patient. ( 27697074 )
2016
17
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. ( 27425586 )
2016
18
Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome? ( 27264342 )
2016
19
Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease? ( 27303314 )
2016
20
Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. ( 27087472 )
2016
21
Repetitive urges to inflict burns: An unusual presentation of impulse control disorder. ( 28163418 )
2016
22
Impulse Control Disorders in Parkinson's Disease are Associated with Alterations in Reward-Related Cortical Oscillations. ( 27372215 )
2016
23
Impaired learning of punishments in Parkinson's disease with and without impulse control disorder. ( 27848033 )
2016
24
Editorial: Exploring Gender and Sex Differences in Behavioral Dyscontrol: From Drug Addiction to Impulse Control Disorders. ( 26941657 )
2016
25
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. ( 26534930 )
2015
26
Impulse control disorder manifesting as hidden sexual self-injury. ( 25828732 )
2015
27
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. ( 25645960 )
2015
28
Idiopathic Basal Ganglia Calcification Presented with Impulse Control Disorder. ( 26246920 )
2015
29
Pet killing as a manifestation of impulse control disorder secondary to pramipexol. ( 25768852 )
2015
30
The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. ( 25447970 )
2015
31
[A^A^C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. ( 25641350 )
2015
32
Impulse control disorders and punding in Perry syndrome. ( 26411500 )
2015
33
Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. ( 23899625 )
2014
34
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse. ( 25362251 )
2014
35
Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? ( 24239733 )
2014
36
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. ( 24971012 )
2014
37
REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson's disease. ( 25085747 )
2014
38
Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. ( 25283069 )
2014
39
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. ( 24434037 )
2014
40
The role of self-awareness and cognitive dysfunction in Parkinson's disease with and without impulse-control disorder. ( 23686032 )
2013
41
The functional anatomy of impulse control disorders. ( 23963609 )
2013
42
Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. ( 23261076 )
2013
43
Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. ( 24045609 )
2013
44
Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders. ( 23714418 )
2013
45
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. ( 23472375 )
2013
46
Pathological generosity: An atypical impulse control disorder after a left subcortical stroke. ( 23962063 )
2013
47
Impulse control disorder in a patient with X-linked dystonia-parkinsonism after bilateral pallidal deep brain stimulation. ( 23920134 )
2013
48
Dopaminergic influences on executive function and impulsive behaviour in impulse control disorders in Parkinson's disease. ( 23901888 )
2013
49
Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. ( 22030321 )
2012
50
Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. ( 23123689 )
2012

Variations for Impulse Control Disorder

Expression for Impulse Control Disorder

Search GEO for disease gene expression data for Impulse Control Disorder.

Pathways for Impulse Control Disorder

GO Terms for Impulse Control Disorder

Cellular components related to Impulse Control Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 8.62 DRD2 DRD3

Biological processes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 synapse assembly GO:0007416 9.65 DRD2 SLITRK1
2 negative regulation of protein kinase B signaling GO:0051898 9.64 DRD2 DRD3
3 circadian regulation of gene expression GO:0032922 9.64 DRD2 DRD3
4 social behavior GO:0035176 9.63 DRD3 DRD4
5 visual learning GO:0008542 9.63 DRD2 DRD3
6 response to cocaine GO:0042220 9.62 DRD2 DRD3
7 positive regulation of cytokinesis GO:0032467 9.62 DRD2 DRD3
8 response to morphine GO:0043278 9.61 DRD2 DRD3
9 negative regulation of blood pressure GO:0045776 9.61 DRD2 DRD3
10 response to amphetamine GO:0001975 9.61 DRD2 DRD3 DRD4
11 adult behavior GO:0030534 9.6 DRD2 SLITRK1
12 regulation of dopamine secretion GO:0014059 9.59 DRD2 DRD3
13 synaptic transmission, dopaminergic GO:0001963 9.58 DRD2 DRD3
14 behavioral response to ethanol GO:0048149 9.58 DRD2 DRD4
15 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
16 positive regulation of renal sodium excretion GO:0035815 9.57 DRD2 DRD3
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.56 DRD2 DRD4
18 prepulse inhibition GO:0060134 9.55 DRD2 DRD3
19 G-protein coupled receptor internalization GO:0002031 9.54 DRD2 DRD3
20 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
21 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.52 DRD2 DRD3
22 acid secretion GO:0046717 9.51 DRD2 DRD3
23 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
24 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.49 DRD2 DRD4
25 negative regulation of dopamine receptor signaling pathway GO:0060160 9.48 DRD2 DRD3
26 regulation of locomotion involved in locomotory behavior GO:0090325 9.46 DRD2 DRD3
27 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
28 dopamine metabolic process GO:0042417 9.33 DRD2 DRD3 DRD4
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
30 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Impulse Control Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD2 DRD3 DRD4
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4
5 protein binding GO:0005515 10.02 ANKK1 CGA CLNK DLGAP3 DNAJB6 DRD2

Sources for Impulse Control Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....